{"protocolSection": {"identificationModule": {"nctId": "NCT01136655", "orgStudyIdInfo": {"id": "D589GC00002"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Study in Asthmatic Children (6 to <12 Yrs) Comparing Single Doses of Formoterol and Foradil\u00ae Evaluating Efficacy", "officialTitle": "A Phase 2, Randomized, Blinded, 5-period Cross-over, Placebo and Active Controlled, Multicenter, Dose-finding Study Comparing Single Doses of Formoterol 2.25 \u00b5g, 4.5 \u00b5g, and 9 \u00b5g Delivered Via Symbicort pMDI and Foradil\u00ae 12 \u00b5g Evaluating the Relative Bronchodilating Effects and Safety in Children", "acronym": "CHASE 2"}, "statusModule": {"statusVerifiedDate": "2013-10", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2010-09"}, "primaryCompletionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "completionDateStruct": {"date": "2011-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2010-06-01", "studyFirstSubmitQcDate": "2010-06-02", "studyFirstPostDateStruct": {"date": "2010-06-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2012-11-12", "resultsFirstSubmitQcDate": "2013-07-23", "resultsFirstPostDateStruct": {"date": "2013-08-30", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2013-10-30", "lastUpdatePostDateStruct": {"date": "2013-10-31", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "This purpose of the study is to investigate the bronchodilating effects of 3 different dosages of formoterol given in combination with budesonide as Symbicort pMDI.", "detailedDescription": "A Phase 2, randomized, blinded, 5-period cross-over, placebo and active controlled, multicenter, dose-finding study comparing single doses of formoterol 2.25 \u00b5g, 4.5 \u00b5g, and 9 \u00b5g delivered via Symbicort pMDI and Foradil\u00ae 12 \u00b5g evaluating the relative bronchodilating effects and safety in children."}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["asthmatic children", "Symbicort", "Foradil"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 54, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "BUD 160/FM 2.25", "type": "EXPERIMENTAL", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI \u00d7 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations", "interventionNames": ["Drug: 80/2.25 \u03bcg Symbicort pMDI", "Drug: 40 \u03bcg budesonide HFA pMDI"]}, {"label": "BUD 160/FM 4.5", "type": "EXPERIMENTAL", "description": "placebo HFA pMDI \u00d7 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI \u00d7 2 inhalations)", "interventionNames": ["Drug: 80/2.25 \u03bcg Symbicort pMDI", "Drug: placebo HFA pMDI"]}, {"label": "BUD 160/FM 9.0", "type": "EXPERIMENTAL", "description": "placebo HFA pMDI \u00d7 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI \u00d7 2 inhalations)", "interventionNames": ["Drug: 80/4.5 \u03bcg Symbicort pMDI", "Drug: placebo HFA pMDI"]}, {"label": "BUD 160", "type": "PLACEBO_COMPARATOR", "description": "placebo HFA pMDI \u00d7 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations", "interventionNames": ["Drug: 40 \u03bcg budesonide HFA pMDI", "Drug: placebo HFA pMDI"]}, {"label": "BUD 160/Foradil 12.0", "type": "ACTIVE_COMPARATOR", "description": "Foradil Aerolizer 12 \u03bcg \u00d7 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations", "interventionNames": ["Drug: Foradil Aerolizer 12 \u03bcg", "Drug: 40 \u03bcg budesonide HFA pMDI"]}], "interventions": [{"type": "DRUG", "name": "80/2.25 \u03bcg Symbicort pMDI", "description": "inhalation", "armGroupLabels": ["BUD 160/FM 2.25", "BUD 160/FM 4.5"]}, {"type": "DRUG", "name": "80/4.5 \u03bcg Symbicort pMDI", "description": "inhalation", "armGroupLabels": ["BUD 160/FM 9.0"]}, {"type": "DRUG", "name": "Foradil Aerolizer 12 \u03bcg", "description": "inhalation", "armGroupLabels": ["BUD 160/Foradil 12.0"]}, {"type": "DRUG", "name": "40 \u03bcg budesonide HFA pMDI", "description": "inhalation", "armGroupLabels": ["BUD 160", "BUD 160/FM 2.25", "BUD 160/Foradil 12.0"]}, {"type": "DRUG", "name": "placebo HFA pMDI", "description": "inhalation", "armGroupLabels": ["BUD 160", "BUD 160/FM 4.5", "BUD 160/FM 9.0"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. FEV1 was obtained from the full expiratory flow-volume-time curve. FEV1 was measured at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes post administration of randomized study medication. Twelve-hour serial FEV1 was calculated through an AUC determination and then divided by time, so that the final value is expressed in liters. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "timeFrame": "at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes postdose"}], "secondaryOutcomes": [{"measure": "FEV1 at 12 Hours After Study Medication Inhalation", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. The FEV1 value at 12 hours after dosing was taken as the 12-hour measurement (720 minutes) from the serial spirometry. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "timeFrame": "12 hours after dosing"}, {"measure": "Maximal FEV1 During the 12-hour Study Period", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. FEV1 was measured at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes post administration of randomized study medication. The maximum FEV1 value was defined as the largest observed FEV1 value recorded during each 12-hour serial spirometry procedure. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "timeFrame": "at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes postdose"}, {"measure": "Urinary Excretion of Formoterol During the 12 Hours Following Inhalation of Study Drug", "description": "The amount of formoterol excreted unchanged in urine over the 12-hour period after administration \\[Ae(0-12h)\\] was calculated from the concentration of formoterol in urine multiplied by the total volume of urine collected. Volume was determined from the weight of the collected urine times an assumed urine density of 1020 g/L. The data for six patients who did not have measurable formoterol in their urine on the Foradil 12 \u03bcg treatment day was excluded from the analysis. All other urine concentrations below the lower limit of quantification were set to zero. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "timeFrame": "0 to 12 hours"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Has a documented clinical diagnosis of asthma for at least 6 months prior to Visit 1\n* Has a FEV1 measured at least 6 hours after the last dose of inhaled, short-acting \u03b22-agonist (SABA) and at least 48 hours after the last dose of inhaled long-acting \u03b22-agonist of =60% and =85% of predicted normal.\n* Demonstrated reversibility of FEV1 of =15% from pre short acting beta agonist level within 15 to 30 minutes after administration of a standard dose of short acting beta agonist\n\nExclusion Criteria:\n\n* Has been hospitalized for \\>24 hours at least once or required emergency treatment or urgent care visit more than once for an asthma-related condition during the 6 months prior to Visit 1\n* Has required treatment with systemic corticosteroids (eg, oral, parenteral, or rectal) for any reason within the 12 weeks prior to Visit 1.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "11 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Lars-Goran Carlsson, MD", "affiliation": "AstraZeneca", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Research Site", "city": "Huntington", "state": "California", "country": "United States"}, {"facility": "Research Site", "city": "Long Beach", "state": "California", "country": "United States", "geoPoint": {"lat": 33.76696, "lon": -118.18923}}, {"facility": "Research Site", "city": "Mission Viejo", "state": "California", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Research Site", "city": "Orange", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Research Site", "city": "Rolling Hills Estate", "state": "California", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Research Site", "city": "Sarasota", "state": "Florida", "country": "United States", "geoPoint": {"lat": 27.33643, "lon": -82.53065}}, {"facility": "Research Site", "city": "Omaha", "state": "Nebraska", "country": "United States", "geoPoint": {"lat": 41.25626, "lon": -95.94043}}, {"facility": "Research Site", "city": "Morrisville", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.82348, "lon": -78.82556}}, {"facility": "Research Site", "city": "Raleigh", "state": "North Carolina", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Research Site", "city": "Eugene", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Research Site", "city": "Lake Oswego", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Research Site", "city": "Medford", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Research Site", "city": "Portland", "state": "Oregon", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Research Site", "city": "Altoona", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 40.51868, "lon": -78.39474}}, {"facility": "Research Site", "city": "Upland", "state": "Pennsylvania", "country": "United States", "geoPoint": {"lat": 39.85261, "lon": -75.38269}}, {"facility": "Research Site", "city": "Charleston", "state": "South Carolina", "country": "United States", "geoPoint": {"lat": 32.77657, "lon": -79.93092}}, {"facility": "Research Site", "city": "El Paso", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Research Site", "city": "San Antonio", "state": "Texas", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Research Site", "city": "Waco", "state": "Texas", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Research Site", "city": "Springfield", "state": "Virginia", "country": "United States", "geoPoint": {"lat": 38.78928, "lon": -77.1872}}, {"facility": "Research Site", "city": "Dublin", "country": "Bulgaria"}, {"facility": "Research Site", "city": "Dublin", "country": "Czech Republic"}, {"facility": "Research Site", "city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"facility": "Research Site", "city": "Dublin", "country": "Hungary"}, {"facility": "Research Site", "city": "Miskolc", "country": "Hungary", "geoPoint": {"lat": 48.1, "lon": 20.78333}}, {"facility": "Research Site", "city": "Sopron", "country": "Hungary", "geoPoint": {"lat": 47.68501, "lon": 16.59049}}, {"facility": "Research Site", "city": "Dublin", "country": "Poland"}, {"facility": "Research Site", "city": "Krugersdorp", "state": "Gauteng", "country": "South Africa", "geoPoint": {"lat": -26.08577, "lon": 27.77515}}, {"facility": "Research Site", "city": "Pietermariztburg", "state": "Kwa Zulu Natal", "country": "South Africa"}, {"facility": "Research Site", "city": "Durban", "state": "Kz-natal", "country": "South Africa", "geoPoint": {"lat": -29.8579, "lon": 31.0292}}, {"facility": "Research Site", "city": "Cape Town", "state": "W Cape", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Claremont", "state": "W Cape", "country": "South Africa", "geoPoint": {"lat": -33.98056, "lon": 18.46528}}, {"facility": "Research Site", "city": "Cape Town", "country": "South Africa", "geoPoint": {"lat": -33.92584, "lon": 18.42322}}, {"facility": "Research Site", "city": "Dublin", "country": "South Africa"}]}, "referencesModule": {"references": [{"pmid": "24717790", "type": "DERIVED", "citation": "Berger WE, Gillen M, Eckerwall G, Uryniak T, Trudo FJ, Lampl KL. Bronchodilator effect of single-dose formoterol administered by pressurized metered-dose inhaler in children with asthma aged 6 to <12 years receiving budesonide. Allergy Asthma Proc. 2014 Mar-Apr;35(2):134-40. doi: 10.2500/aap.2014.35.3746."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "The study consisted of a screening visit, an enrolment visit, a 1- to 2-week run-in (standardization) period, randomization at Visit 3, and 4 further visits (Visits 4-7)separated by approximately 7-day (minimum 3 days; maximum 14 days) wash-out (stabilization) periods. Subjects received 1 of 5 single-dose treatments at Visits 3-7, in random order.", "recruitmentDetails": "This multicenter study was conducted in Europe and the United States between 7 October 2010 and 3 January 2012.", "groups": [{"id": "FG000", "title": "Randomized Patients", "description": "All randomized patients"}], "periods": [{"title": "BUD 160/FM 2.25 (1 Dose)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Washout After BUD 160/FM 2.25 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "54"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "BUD 160/FM 4.5 (1 Dose)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Washout After BUD 160/FM 4.5 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "52"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "1"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "BUD 160/FM 9.0 (1 Dose)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Washout After BUD 160/FM 9.0 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "53"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "2"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}]}, {"title": "BUD 160 (1 Dose)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Washout After BUD 160 (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "51"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "BUD 160/ Foradil 12.0 (1 Dose)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}, {"title": "Washout After BUD 160/ Foradil (7 Days)", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "50"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Randomized Patients", "description": "All randomized patients"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "54"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "9.2", "spread": "1.79"}]}]}]}, {"title": "Age, Customized", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": ">=6 to <8 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "11"}]}]}, {"title": ">=8 to < 12 years", "categories": [{"measurements": [{"groupId": "BG000", "value": "43"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "23"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "31"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "22"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "31"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "1"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Average 12 Hour Forced Expiratory Volume in 1 Second (FEV1)", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. FEV1 was obtained from the full expiratory flow-volume-time curve. FEV1 was measured at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes post administration of randomized study medication. Twelve-hour serial FEV1 was calculated through an AUC determination and then divided by time, so that the final value is expressed in liters. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "populationDescription": "Efficacy analysis set including all patients who were randomized (defined as having a randomization code recorded on the demography case report form), received at least one dose of study medication, and contributed sufficient data for at least one efficacy endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes postdose", "groups": [{"id": "OG000", "title": "BUD 160/FM 2.25", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}, {"id": "OG001", "title": "BUD 160/FM 4.5", "description": "placebo HFA pMDI x 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG002", "title": "BUD 160/FM 9.0", "description": "placebo HFA pMDI x 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG003", "title": "BUD 160", "description": "placebo HFA pMDI x 1 inhalation + 80 \u03bcg budesonide HFA pMDI x 2 inhalations"}, {"id": "OG004", "title": "BUD 160/ Foradil 12.0", "description": "Foradil Aerolizer 12 \u03bcg x 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.546", "spread": "0.0097"}, {"groupId": "OG001", "value": "1.594", "spread": "0.0099"}, {"groupId": "OG002", "value": "1.603", "spread": "0.0099"}, {"groupId": "OG003", "value": "1.489", "spread": "0.0101"}, {"groupId": "OG004", "value": "1.603", "spread": "0.0101"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment", "paramType": "LS mean difference", "paramValue": "0.114", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.087", "ciUpperLimit": "0.142", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0140"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.105", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.078", "ciUpperLimit": "0.133", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0140"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.058", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.030", "ciUpperLimit": "0.085", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0141"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5223", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.009", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.036", "ciUpperLimit": "0.018", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0139"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.057", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.084", "ciUpperLimit": "-0.029", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0139"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0007", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.048", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.075", "ciUpperLimit": "-0.020", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0138"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.114", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.142", "ciUpperLimit": "-0.086", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0141"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.056", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.084", "ciUpperLimit": "-0.028", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0141"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5394", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.009", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.036", "ciUpperLimit": "0.019", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0141"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.9863", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.000", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.027", "ciUpperLimit": "0.028", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0140"}]}, {"type": "SECONDARY", "title": "FEV1 at 12 Hours After Study Medication Inhalation", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. The FEV1 value at 12 hours after dosing was taken as the 12-hour measurement (720 minutes) from the serial spirometry. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "populationDescription": "Efficacy analysis set including all patients who were randomized (defined as having a randomization code recorded on the demography case report form), received at least one dose of study medication, and contributed sufficient data for at least one efficacy endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "12 hours after dosing", "groups": [{"id": "OG000", "title": "BUD 160/FM 2.25", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}, {"id": "OG001", "title": "BUD 160/FM 4.5", "description": "placebo HFA pMDI x 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG002", "title": "BUD 160/FM 9.0", "description": "placebo HFA pMDI x 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG003", "title": "BUD 160", "description": "placebo HFA pMDI x 1 inhalation + 80 \u03bcg budesonide HFA pMDI x 2 inhalations"}, {"id": "OG004", "title": "BUD 160/ Foradil 12.0", "description": "Foradil Aerolizer 12 \u03bcg x 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.641", "spread": "0.0175"}, {"groupId": "OG001", "value": "1.692", "spread": "0.0177"}, {"groupId": "OG002", "value": "1.731", "spread": "0.0177"}, {"groupId": "OG003", "value": "1.626", "spread": "0.0181"}, {"groupId": "OG004", "value": "1.709", "spread": "0.0182"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.105", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.056", "ciUpperLimit": "0.155", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0250"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0092", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.066", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.017", "ciUpperLimit": "0.116", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0252"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5509", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.035", "ciUpperLimit": "0.065", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0252"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1163", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.039", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.088", "ciUpperLimit": "0.010", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0249"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0004", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.090", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.140", "ciUpperLimit": "-0.041", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0250"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0400", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.051", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.100", "ciUpperLimit": "-0.002", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0247"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.083", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.133", "ciUpperLimit": "-0.034", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0252"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0077", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.068", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.118", "ciUpperLimit": "-0.018", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0254"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4957", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "-0.017", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.067", "ciUpperLimit": "0.033", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0252"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Factors in the ANCOVA model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.3800", "statisticalMethod": "ANCOVA", "statisticalComment": "LOCF was performed if missing data were post last non-missing post-baseline assessment.", "paramType": "LS mean difference", "paramValue": "0.022", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.027", "ciUpperLimit": "0.071", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0250"}]}, {"type": "SECONDARY", "title": "Maximal FEV1 During the 12-hour Study Period", "description": "Pulmonary function tests consisted of 3 forced expiratory maneuvers in which the patient expired forcefully from total lung capacity to residual volume, recorded using a spirometer. FEV1 was measured at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes post administration of randomized study medication. The maximum FEV1 value was defined as the largest observed FEV1 value recorded during each 12-hour serial spirometry procedure. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "populationDescription": "Efficacy analysis set including all patients who were randomized (defined as having a randomization code recorded on the demography case report form), received at least one dose of study medication, and contributed sufficient data for at least one efficacy endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "liters", "timeFrame": "at 3, 9, 15, 60, 120, 180, 240, 360, 480, 600 and 720 minutes postdose", "groups": [{"id": "OG000", "title": "BUD 160/FM 2.25", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}, {"id": "OG001", "title": "BUD 160/FM 4.5", "description": "placebo HFA pMDI x 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG002", "title": "BUD 160/FM 9.0", "description": "placebo HFA pMDI x 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG003", "title": "BUD 160", "description": "placebo HFA pMDI x 1 inhalation + 80 \u03bcg budesonide HFA pMDI x 2 inhalations"}, {"id": "OG004", "title": "BUD 160/ Foradil 12.0", "description": "Foradil Aerolizer 12 \u03bcg x 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "54"}, {"groupId": "OG001", "value": "53"}, {"groupId": "OG002", "value": "53"}, {"groupId": "OG003", "value": "51"}, {"groupId": "OG004", "value": "51"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1.833", "spread": "0.0119"}, {"groupId": "OG001", "value": "1.889", "spread": "0.0120"}, {"groupId": "OG002", "value": "1.884", "spread": "0.0120"}, {"groupId": "OG003", "value": "1.777", "spread": "0.0123"}, {"groupId": "OG004", "value": "1.892", "spread": "0.0123"}]}]}], "analyses": [{"groupIds": ["OG002", "OG003"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "0.107", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.073", "ciUpperLimit": "0.140", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0170"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "0.112", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.078", "ciUpperLimit": "0.146", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0171"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "0.057", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.023", "ciUpperLimit": "0.090", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0172"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.7589", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "0.005", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.028", "ciUpperLimit": "0.039", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0169"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0035", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.050", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.084", "ciUpperLimit": "-0.017", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0170"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0011", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.055", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.089", "ciUpperLimit": "-0.022", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0168"}, {"groupIds": ["OG003", "OG004"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.115", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.149", "ciUpperLimit": "-0.081", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0171"}, {"groupIds": ["OG000", "OG004"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0008", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.058", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.092", "ciUpperLimit": "-0.024", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0172"}, {"groupIds": ["OG001", "OG004"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.8582", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.003", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.037", "ciUpperLimit": "0.031", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0172"}, {"groupIds": ["OG002", "OG004"], "groupDescription": "Factors in the Analysis of Covariance model included: patient, visit, treatment, and the covariate pre-dose FEV1 from each visit.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.6276", "statisticalMethod": "ANCOVA", "paramType": "LS mean difference", "paramValue": "-0.008", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.042", "ciUpperLimit": "0.025", "dispersionType": "STANDARD_ERROR_OF_MEAN", "dispersionValue": "0.0170"}]}, {"type": "SECONDARY", "title": "Urinary Excretion of Formoterol During the 12 Hours Following Inhalation of Study Drug", "description": "The amount of formoterol excreted unchanged in urine over the 12-hour period after administration \\[Ae(0-12h)\\] was calculated from the concentration of formoterol in urine multiplied by the total volume of urine collected. Volume was determined from the weight of the collected urine times an assumed urine density of 1020 g/L. The data for six patients who did not have measurable formoterol in their urine on the Foradil 12 \u03bcg treatment day was excluded from the analysis. All other urine concentrations below the lower limit of quantification were set to zero. One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "populationDescription": "Efficacy analysis set including all patients who were randomized (defined as having a randomization code recorded on the demography case report form), received at least one dose of study medication, and contributed sufficient data for at least one efficacy endpoint.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "pmol", "timeFrame": "0 to 12 hours", "groups": [{"id": "OG000", "title": "BUD 160/FM 2.25", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}, {"id": "OG001", "title": "BUD 160/FM 4.5", "description": "placebo HFA pMDI x 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG002", "title": "BUD 160/FM 9.0", "description": "placebo HFA pMDI x 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI x 2 inhalations)"}, {"id": "OG003", "title": "BUD 160/ Foradil 12.0", "description": "Foradil Aerolizer 12 \u03bcg x 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "51"}, {"groupId": "OG001", "value": "52"}, {"groupId": "OG002", "value": "51"}, {"groupId": "OG003", "value": "43"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "192.0", "lowerLimit": "156.36", "upperLimit": "235.88"}, {"groupId": "OG001", "value": "366.3", "lowerLimit": "298.85", "upperLimit": "448.96"}, {"groupId": "OG002", "value": "740.6", "lowerLimit": "602.45", "upperLimit": "910.51"}, {"groupId": "OG003", "value": "658.7", "lowerLimit": "522.61", "upperLimit": "830.24"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "0.52", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.393", "ciUpperLimit": "0.700"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "0.26", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.194", "ciUpperLimit": "0.347"}, {"groupIds": ["OG000", "OG003"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "0.29", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.214", "ciUpperLimit": "0.396"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "0.49", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.371", "ciUpperLimit": "0.659"}, {"groupIds": ["OG001", "OG003"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0002", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "0.56", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.409", "ciUpperLimit": "0.755"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Factors in the ANOVA model included: patient, period and treatment.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.4512", "statisticalMethod": "ANOVA", "statisticalComment": "A shift log transformation was performed on the response variable in the ANOVA model, using log(response) \\[log(response + 1) if response is 0\\].", "paramType": "LS mean difference", "paramValue": "1.12", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.827", "ciUpperLimit": "1.528"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "One subject was incorrectly administered BUD 160/ formoterol (FM) 9.0 rather than BUD 160/ Foradil 12.0 at Period 4. Hence this subject is included in the Efficacy Analysis Set, but not the Safety Analysis Set for BUD 160/ Foradil 12.0.", "eventGroups": [{"id": "EG000", "title": "BUD 160/FM 2.25", "description": "2.25 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 1 inhalation) + 40 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations", "seriousNumAffected": 0, "seriousNumAtRisk": 54, "otherNumAffected": 1, "otherNumAtRisk": 54}, {"id": "EG001", "title": "BUD 160/FM 4.5", "description": "placebo HFA pMDI x 1 inhalation + 4.5 \u03bcg formoterol (as 80/2.25 \u03bcg Symbicort pMDI x 2 inhalations)", "seriousNumAffected": 0, "seriousNumAtRisk": 53, "otherNumAffected": 1, "otherNumAtRisk": 53}, {"id": "EG002", "title": "BUD 160/FM 9.0", "description": "placebo HFA pMDI x 1 inhalation + 9 \u03bcg formoterol (as 80/4.5 \u03bcg Symbicort pMDI x 2 inhalations)", "seriousNumAffected": 0, "seriousNumAtRisk": 53, "otherNumAffected": 5, "otherNumAtRisk": 53}, {"id": "EG003", "title": "BUD 160", "description": "placebo HFA pMDI x 1 inhalation + 80 \u03bcg budesonide HFA pMDI x 2 inhalations", "seriousNumAffected": 0, "seriousNumAtRisk": 51, "otherNumAffected": 2, "otherNumAtRisk": 51}, {"id": "EG004", "title": "BUD 160/ Foradil 12.0", "description": "Foradil Aerolizer 12 \u03bcg x 1 inhalation + 80 \u03bcg budesonide HFA pMDI \u00d7 2 inhalations", "seriousNumAffected": 0, "seriousNumAtRisk": 50, "otherNumAffected": 0, "otherNumAtRisk": 50}], "otherEvents": [{"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 14.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 54}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 53}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 53}, {"groupId": "EG003", "numAffected": 2, "numAtRisk": 51}, {"groupId": "EG004", "numAffected": 0, "numAtRisk": 50}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "G\u00f6ran Eckerwall, MSD", "organization": "AstraZeneca", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"browseLeaves": [{"id": "M4556", "name": "Asthma", "relevance": "LOW"}, {"id": "T4202", "name": "Oculocerebral Syndrome With Hypopigmentation", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC20", "name": "Immune System Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000019819", "term": "Budesonide"}, {"id": "D000068759", "term": "Formoterol Fumarate"}, {"id": "D000069502", "term": "Budesonide, Formoterol Fumarate Drug Combination"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000005938", "term": "Glucocorticoids"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M21711", "name": "Budesonide", "asFound": "Of 1", "relevance": "HIGH"}, {"id": "M304", "name": "Formoterol Fumarate", "asFound": "Prednisone 5 mg", "relevance": "HIGH"}, {"id": "M452", "name": "Budesonide, Formoterol Fumarate Drug Combination", "asFound": "Early Stage", "relevance": "HIGH"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M9047", "name": "Glucocorticoids", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}